Valuation : AstraZeneca PLC

Market Cap 255B 219B 206B 188B 352B 24,107B 354B 2,436B 949B 12,320B 958B 937B 39,677B P/E 2026 *
21.2x
P/E 2027 * 18.5x
Enterprise Value 274B 236B 222B 203B 378B 25,947B 381B 2,622B 1,021B 13,260B 1,031B 1,008B 42,705B EV / Sales 2026 *
4.34x
EV / Sales 2027 * 3.99x
Free-Float
96.63%
Yield 2026 *
2.03%
Yield 2027 * 2.17%
1 day+1.94%
Current month+77.61%
Current year+79.23%
Current year 89.04
Extreme 89.04
165.74
1 year 72.9
Extreme 72.895
165.74
3 years 60.47
Extreme 60.47
165.74
5 years 52.65
Extreme 52.65
165.74
10 years 25.55
Extreme 25.55
165.74
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%+0.15% - - 255B
-0.04%-1.40%+57.16%+108.15% 1,034B
+1.17%+4.76%+56.42%+73.50% 671B
-0.58%+0.80%+22.82%+75.58% 460B
+2.09%-2.06%+32.28%+37.41% 353B
0.00%+5.36%+27.40%+46.97% 309B
+1.42%+0.26%-0.52%+13.51% 255B
+0.29%+1.63%+56.46%+73.00% 240B
-0.03%+2.13%-17.30%-53.65% 207B
+1.08%+1.59%+33.83%+97.29% 188B
Average +0.68%+1.27%+29.84%+52.42% 412.97B
Weighted average by Cap. +0.45%+1.04%+38.60%+67.71%

Financials

2026 *2027 *
Net sales 63.24B 54.41B 51.06B 46.72B 87.19B 5,978B 87.88B 604B 235B 3,055B 237B 232B 9,839B 66.84B 57.51B 53.97B 49.38B 92.16B 6,318B 92.89B 638B 249B 3,229B 251B 246B 10,399B
Net income 12.01B 10.34B 9.7B 8.87B 16.56B 1,136B 16.69B 115B 44.68B 580B 45.11B 44.12B 1,869B 13.69B 11.78B 11.05B 10.11B 18.88B 1,294B 19.03B 131B 50.93B 661B 51.42B 50.29B 2,130B
Net Debt 19.46B 16.75B 15.71B 14.38B 26.83B 1,840B 27.05B 186B 72.39B 940B 73.08B 71.49B 3,028B 11.79B 10.14B 9.52B 8.71B 16.25B 1,114B 16.38B 113B 43.85B 569B 44.27B 43.3B 1,834B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-09-03 US$164.77 +1.94% 2,425,271
26-09-02 US$161.63 -0.52% 3,301,432
26-09-01 US$162.47 +0.21% 2,598,488
26-08-31 US$162.13 -0.35% 3,068,214
26-08-28 US$162.70 -1.11% 2,880,829
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
164.42USD
Average target price
212.82USD
Spread / Average Target
+29.44%

Quarterly revenue - Rate of surprise